Results 131 to 140 of about 22,015 (248)

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Advancing IBD Management: A Literature Review on the Role of Non‐Invasive Blood‐Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Reliable biomarkers that enable noninvasive, longitudinal assessment of disease activity and therapeutic response remain a major unmet need in inflammatory bowel disease (IBD). While colonic biopsies are the gold standard for evaluating mucosal inflammation, their invasive nature and limited spatial and temporal resolution constrain their ...
Mohamed Hassanein, Li Xi, Rathi D. Ryan, Zhan (Harold) Ye, Nessy Tania, Yamato Sano, Joshua Varghese, Diogo Branquinho, Anna Sapone   +8 more
wiley   +1 more source

Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Using a real‐world psoriasis cohort, we established the pharmacokinetic‐pharmacodynamic (PKPD) relationship for the biologic therapy adalimumab and evaluated the clinical utility and cost‐effectiveness of a proactive therapeutic drug monitoring (TDM) strategy.
Shan Pan, Teresa Tsakok, Ruoheng Wei, Nick Dand, Floris C. Loeff, Karien Bloem, Annick de Vries, David Baudry, Michael Duckworth, Angela Pushpa‐Rajah, Alice Russell, Ali Alsharqi, Gabrielle Becher, Ruth Murphy, Shyamal Wahie, Andrew Wright, Christopher E. M. Griffiths, Nick J. Reynolds, Jonathan Barker, Richard B. Warren, A. David Burden, Theo Rispens, Satveer K. Mahil, Joseph F. Standing, Catherine H. Smith, on behalf of the BADBIR Study Group, the BSTOP Study Group and the PSORT Consortium, Marilyn Benham, Sagair Hussain, Brian Kirby, Linda Lawson, Kathleen McElhone, Anthony Ormerod, Caroline Owen, Michael R. Barnes, Paola Di Meglio, Richard Emsley, Andrea Evans, Katherine Payne   +38 more
wiley   +1 more source

AI‐Enhanced Vibrational Capsule for Minimally Invasive Detection of Abnormal Bowel Tissue

Advanced Science, Volume 13, Issue 23, 23 April 2026.
A fully integrated vibration‐assisted capsule is presented for the minimally invasive detection of bowel lesions. The capsule incorporates a wireless sensor and an eccentric motor to probe tissue mechanics in situ. By coupling triaxial vibration signals with AI‐based classification and analytical modeling, the system enables early, non‐visual ...
Xizheng Fang, Yao Yan, Kenneth Omokhagbo Afebu, Andrew Bickerdike, Bo Tian, Yang Liu, Shyam Prasad   +6 more
wiley   +1 more source

Exploring Affordable Curative Therapy for Sickle Cell Disease in Africa: A Comprehensive Overview

American Journal of Hematology, Volume 101, Issue S1, Page 56-74, April 2026.
ABSTRACT The practical aspects of developing curative treatments for sickle cell disease (SCD) in Africa, such as gene therapy and hematopoietic stem cell transplantation, involve strengthening healthcare infrastructure, training healthcare professionals, establishing regional treatment centers, and creating national SCD programs.
Adetola A. Kassim, Alexis A. Thompson, Punam Malik   +2 more
wiley   +1 more source

Biosimilars in der Schweiz : Medizin gegen die steigenden Gesundheitskosten? [PDF]

, 2020
Kobler, Irene, Lenzin, Golda, Liberatore, Florian, Pöhlmann, Johannes, Schmidt, Marion, Wieser, Simon   +5 more
core   +1 more source

Use of anti–amyloid‐β monoclonal antibodies in persons with Down syndrome Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.
Abstract INTRODUCTION The recent development and licensing of anti–amyloid‐β monoclonal antibodies for the treatment of early‐stage Alzheimer's disease have significantly shifted the clinical landscape. However, current use recommendations preclude the administration of these new drugs to persons who have Down syndrome.
Clíona Farrell, Fedal Saini, Mona M. Beidas, Natalie S. Ryan, Andre Strydom, Frances K. Wiseman   +5 more
wiley   +1 more source

A Phase 3 Multicenter, Double‐Blind Study Comparing Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Alkem's Biosimilar Teriparatide Versus Reference Teriparatide in Postmenopausal Osteoporosis

Aging Medicine
Objective The primary purpose of this study was to compare the efficacy and safety of proposed biosimilar teriparatide with reference teriparatide in patients of postmenopausal osteoporosis.
Nitin Kapoor, Thomas Paul, Rajeshwar Nath Srivastava, Saurabh Singh, Sunil Maheshwari, Vishal Patil, Awadhesh Kumar Yadav, Girish Bhatia, Sushil H. Mankar, Joe Joseph Cherian, Surabhi Maheshwari, Sudeepti Srivastava, Dattatray Pawar, Roshan Pawar, Amol Aiwale, Amitrajit Pal, Yogesh Rane, Vinayaka Shahavi, Akhilesh Sharma   +18 more
doaj   +1 more source

Lab‐Scale Continuous Biomanufacturing: A Tool for Process Development With Adaptive Strategies for Capture and Virus Inactivation

Biotechnology and Bioengineering, Volume 123, Issue 4, Page 924-938, April 2026.
Schematic representation of the continuous lab‐scale process. ABSTRACT Monoclonal antibodies (mAbs) are nowadays fundamental in treating a wide range of severe diseases, including cancer, infections, or autoimmune disorders. Due to their high specificity, potent activity, and fewer side effects compared to small molecular drugs, the market for mAbs is ...
Thomas Kruse, Fabian Schmitz, Janina Kilian, Jonas Austerjost, Lucas‐Nik Reger, Markus Kampmann   +5 more
wiley   +1 more source

Biopharmaceuticals for Cancer Treatment: An Update

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Anupom Deb Nath, Yousuf Alam, Afsana Mustak Mim, Maksuda Akter, Mohammad Abbas Gani, Khondaker Muhammad Khairul Alam, Md. Nur Alam   +6 more
wiley   +1 more source